Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platelet transfusion is a biological therapy involving the intravenous administration of platelet concentrates to prevent or treat bleeding in patients with thrombocytopenia or platelet dysfunction. Platelets are cell fragments derived from megakaryocytes that play a critical role in primary hemostasis by adhering to sites of vascular injury, aggregating to form a platelet plug, and providing a surface for the assembly of coagulation factor complexes. In the context of the ECSTATIC trial led by Yale University, researchers are investigating optimal hemostatic transfusion strategies for critically ill children supported by extracorporeal membrane oxygenation (ECMO). The study specifically compares higher versus lower platelet count thresholds for triggering prophylactic transfusions to balance the prevention of hemorrhage against the potential morbidity and mortality associated with large-volume transfusions in this vulnerable population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on platelet transfusion (Yale University).